| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vivo |
SKF 83822 (25-100 μg/kg; subcutaneous injection; single dose following administration of numerous antioxidants) generates a robust rotating reaction throughout the body in a dose-dependent manner. SKF 83822 also promotes high expression of IEG products c-Fos, Fra2, Zif/268 and Arc in the denervated striatum [1]. SKF 83822 demonstrated substantial effects in monkeys at the mid- and high-dose of 0.25 mg/kg and 0.35 mg/kg, respectively. However, SKF 83822 (0.15- 0.35 mg/kg; subcutaneous injection; single dose) produces movement but not dyskinesia. SKF 83822 creates a condition of high excitation and motor activity without stereotypy [2].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) derived rat [1] ]
Doses: 6.25μg/kg, 25μg/kg, 50μg/kg, 100μg/kg; with or without 0.5 mg/kg antagonist SCH 23390. Route of Administration: SC; single dose, 30 minutes after antagonist treatment. Experimental Results: A strong rotational response was produced at the 50 μg/kg dose, approximately halfway between the responses produced by the 25 μg/kg and 100 μg/kg doses in the first experiment. Can be inhibited by the dopamine D1 receptor antagonist SCH 23390. |
| References |
[1]. Wirtshafter D. Rotation and immediate-early gene expression in rats treated with the atypical D1 dopamine agonist SKF 83822. Pharmacol Biochem Behav. 2007 Mar;86(3):505-10.
[2]. Peacock L, et al. Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions. Biol Psychiatry. 2001 Oct 1;50(7):501-9. |
| Molecular Formula |
C20H22NO2CL.HBR
|
|---|---|
| Molecular Weight |
424.75912
|
| CAS # |
74115-08-5
|
| Related CAS # |
SKF83822 hydrobromide;74115-10-9
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
Br.C=CCN1CCC2=C(C(=C(C=C2C(C2=CC=CC(C)=C2)C1)O)O)Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~290.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3543 mL | 11.7714 mL | 23.5427 mL | |
| 5 mM | 0.4709 mL | 2.3543 mL | 4.7085 mL | |
| 10 mM | 0.2354 mL | 1.1771 mL | 2.3543 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
